Delivery Order SPE2DB20D2002-SPE2DB24FL59F
- Not listed
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,062.57, is for the delivery of RYTARY ER 61.25 MG-245 MG CAP 100S, a pharmaceutical product. The contract has an ultimate completion date of July 16, 2024, and is a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,248.50 firm fixed-price delivery order contract is for the provision of RYTARY ER 48.75 MG-195 MG CAP 100S, a specialty pharmaceutical product. The contract has an ultimate completion date of May 2, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, worth $28,874.37, is for the delivery of RYTARY ER 48.75 MG-195 MG CAP 100S, a pharmaceutical product. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,555.66, is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The award covers the supply of RYTARY ER 48.75 MG-195 MG CAP 100S, a pharmaceutical product, to...
- This federal contract award, valued at $1,741.73, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RYTARY ER 23.75 MG-95 MG CAP 100S, a prescription medication. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,155.82, is a delivery order for the supply of RYTARY ER 61.25 MG-245 MG CAP 100S, a pharmaceutical product. The contract has an ultimate completion date of February 4, 2025 and is a firm fixed-price contract. This order is part of a larger Indefinite Delivery Contract (IDC) that...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,604.93, is for the delivery of RYTARY ER 23.75 MG-95 MG CAP 100S, a prescription medication. The contract is a Delivery Order under a Firm Fixed Price contract type, with a completion date of September 4, 2024. The award is not designated as a set-aside contract. Amerisourcebergen Drug Corp...
- This is a federal contract award made by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,374.59, is for the delivery of RYTARY ER 48.75 MG-195 MG CAP 100S, a pharmaceutical product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RYTARY ER 48.75 MG-195 MG CAP 100S, a medication. The contract is a Delivery Order with a Firm Fixed Price of $13,353.09 and a completion date of January 15, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,814.95, is a firm fixed-price delivery order for the pharmaceutical product RYTARY ER 36.25 MG-145 MG CAP 100S. The contract has an ultimate completion date of November 13, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- SPE2DB20D2002Indefinite Delivery Contract
- SPE2DB20D2002-SPE2DB24FL59FDelivery Order
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,816.61, is for the delivery of RYTARY ER 48.75 MG-195 MG CAP 100S, a medication. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen is a for-profit organization registered in the System for Award Management (SAM.gov) and has established itself as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems. The company maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 6/6/24 |